Sandra Milligan - 14 May 2024 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Role
Director
Signature
/s/ Heidy King-Jones, as Attorney-in-Fact
Issuer symbol
SYRE
Transactions as of
14 May 2024
Net transactions value
$0
Form type
4
Filing time
16 May 2024, 16:10:27 UTC
Previous filing
06 May 2024
Next filing
06 Jun 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRE Stock Option (Right to Buy) Award $0 +21,980 $0.000000 21,980 14 May 2024 Common Stock 21,980 $39.29 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents a right to purchase 21,980 shares of the Issuer's common stock, which will vest and become exercisable in 36 equal monthly installments following May 14, 2024 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date.